{"id":39550,"date":"2024-07-17T11:42:23","date_gmt":"2024-07-17T11:42:23","guid":{"rendered":"https:\/\/ibima.eu\/?p=39550"},"modified":"2024-07-17T11:42:26","modified_gmt":"2024-07-17T11:42:26","slug":"recombinant-soluble-isoform-of-the-human-ifnss-receptor-isol-as-a-potential-therapeutic-molecule-for-multiple-sclerosis","status":"publish","type":"post","link":"https:\/\/ibima.eu\/es\/recombinant-soluble-isoform-of-the-human-ifnss-receptor-isol-as-a-potential-therapeutic-molecule-for-multiple-sclerosis\/","title":{"rendered":"RECOMBINANT SOLUBLE ISOFORM OF THE HUMAN IFNSS RECEPTOR (ISOL) AS A POTENTIAL THERAPEUTIC MOLECULE FOR MULTIPLE SCLEROSIS"},"content":{"rendered":"\n[et_pb_section fb_built=\u00bb1″ _builder_version=\u00bb4.25.0″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_row column_structure=\u00bb2_3,1_3″ _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb30px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_column type=\u00bb2_3″ _builder_version=\u00bb4.25.0″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_text _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb hover_enabled=\u00bb0″ global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb sticky_enabled=\u00bb0″]
\n
\n
\n
\n
\n
\n

Financed by<\/strong>: European Commission<\/span><\/p>\n

Programme<\/strong>: INEXT- INFRASTRUCTURE FOR NMR, EM AND X-RAYS FOR TRANSLATIONAL RESEARCH 2018<\/span><\/p>\n

Grant Agreement ID:\u00a0<\/b>CE-INFRA-INEXT-2018-01\u00a0<\/span><\/p>\n

\u00a0<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n

\n
\n
\n
\n
\n
\n

Contact:\u00a0Laricchia-Robbio, Leopoldo<\/span><\/p>\n

Implementation Centre:<\/strong><\/span>\u00a0Hospital\u00a0Regional Universitario de M\u00e1laga<\/a><\/span><\/p>\n

Research group of IBIMA involved:<\/span>\u00a0<\/span>Neuroimmunology and Neuroinflammation<\/a><\/span><\/p>\n

 <\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_3″ _builder_version=\u00bb4.25.0″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_post_title title=\u00bboff\u00bb meta=\u00bboff\u00bb image_height=\u00bb1000px\u00bb image_max_height=\u00bb115px\u00bb admin_label=\u00bbT\u00edtulo de publicaci\u00f3n\u00bb _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb title_font=\u00bbArial||||||||\u00bb title_text_align=\u00bbcenter\u00bb title_text_color=\u00bb#2ea3f2″ title_font_size=\u00bb35px\u00bb meta_text_align=\u00bbcenter\u00bb background_enable_color=\u00bboff\u00bb background_enable_image=\u00bboff\u00bb text_orientation=\u00bbcenter\u00bb width=\u00bb100%\u00bb max_width=\u00bb89%\u00bb module_alignment=\u00bbcenter\u00bb min_height=\u00bb100px\u00bb height=\u00bb100px\u00bb max_height=\u00bb100px\u00bb custom_margin=\u00bb27%||1%||false|false\u00bb hover_enabled=\u00bb0″ title_font_size_last_edited=\u00bboff|desktop\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb sticky_enabled=\u00bb0″][\/et_pb_post_title][\/et_pb_column][\/et_pb_row][\/et_pb_section]\n","protected":false},"excerpt":{"rendered":"

Financed by: European Commission Programme: INEXT- INFRASTRUCTURE FOR NMR, EM AND X-RAYS FOR TRANSLATIONAL RESEARCH 2018 Grant Agreement ID:\u00a0CE-INFRA-INEXT-2018-01\u00a0 \u00a0 Contact:\u00a0Laricchia-Robbio, Leopoldo Implementation Centre:\u00a0Hospital\u00a0Regional Universitario de M\u00e1laga Research group of IBIMA involved:\u00a0Neuroimmunology and Neuroinflammation  <\/p>\n","protected":false},"author":2,"featured_media":39552,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2191],"tags":[],"class_list":["post-39550","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-proyectos-de-investigacion"],"acf":[],"yoast_head":"\nRECOMBINANT SOLUBLE ISOFORM OF THE HUMAN IFNSS RECEPTOR (ISOL) AS A POTENTIAL THERAPEUTIC MOLECULE FOR MULTIPLE SCLEROSIS - Ibima<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibima.eu\/es\/recombinant-soluble-isoform-of-the-human-ifnss-receptor-isol-as-a-potential-therapeutic-molecule-for-multiple-sclerosis\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RECOMBINANT SOLUBLE ISOFORM OF THE HUMAN IFNSS RECEPTOR (ISOL) AS A POTENTIAL THERAPEUTIC MOLECULE FOR MULTIPLE SCLEROSIS - Ibima\" \/>\n<meta property=\"og:description\" content=\"Financed by: European Commission Programme: INEXT- INFRASTRUCTURE FOR NMR, EM AND X-RAYS FOR TRANSLATIONAL RESEARCH 2018 Grant Agreement ID:\u00a0CE-INFRA-INEXT-2018-01\u00a0 \u00a0 Contact:\u00a0Laricchia-Robbio, Leopoldo Implementation Centre:\u00a0Hospital\u00a0Regional Universitario de M\u00e1laga Research group of IBIMA involved:\u00a0Neuroimmunology and Neuroinflammation  \" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibima.eu\/es\/recombinant-soluble-isoform-of-the-human-ifnss-receptor-isol-as-a-potential-therapeutic-molecule-for-multiple-sclerosis\/\" \/>\n<meta property=\"og:site_name\" content=\"Ibima\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-17T11:42:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-07-17T11:42:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/07\/Human-IFNs-receptor-iSOL.png\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"prodriguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"prodriguez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/recombinant-soluble-isoform-of-the-human-ifnss-receptor-isol-as-a-potential-therapeutic-molecule-for-multiple-sclerosis\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/recombinant-soluble-isoform-of-the-human-ifnss-receptor-isol-as-a-potential-therapeutic-molecule-for-multiple-sclerosis\\\/\"},\"author\":{\"name\":\"prodriguez\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"headline\":\"RECOMBINANT SOLUBLE ISOFORM OF THE HUMAN IFNSS RECEPTOR (ISOL) AS A POTENTIAL THERAPEUTIC MOLECULE FOR MULTIPLE SCLEROSIS\",\"datePublished\":\"2024-07-17T11:42:23+00:00\",\"dateModified\":\"2024-07-17T11:42:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/recombinant-soluble-isoform-of-the-human-ifnss-receptor-isol-as-a-potential-therapeutic-molecule-for-multiple-sclerosis\\\/\"},\"wordCount\":268,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/recombinant-soluble-isoform-of-the-human-ifnss-receptor-isol-as-a-potential-therapeutic-molecule-for-multiple-sclerosis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ibima.eu\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/Human-IFNs-receptor-iSOL.png\",\"articleSection\":[\"Proyectos de Investigaci\u00f3n\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/recombinant-soluble-isoform-of-the-human-ifnss-receptor-isol-as-a-potential-therapeutic-molecule-for-multiple-sclerosis\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/recombinant-soluble-isoform-of-the-human-ifnss-receptor-isol-as-a-potential-therapeutic-molecule-for-multiple-sclerosis\\\/\",\"url\":\"https:\\\/\\\/ibima.eu\\\/recombinant-soluble-isoform-of-the-human-ifnss-receptor-isol-as-a-potential-therapeutic-molecule-for-multiple-sclerosis\\\/\",\"name\":\"RECOMBINANT SOLUBLE ISOFORM OF THE HUMAN IFNSS RECEPTOR (ISOL) AS A POTENTIAL THERAPEUTIC MOLECULE FOR MULTIPLE SCLEROSIS - Ibima\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/recombinant-soluble-isoform-of-the-human-ifnss-receptor-isol-as-a-potential-therapeutic-molecule-for-multiple-sclerosis\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/recombinant-soluble-isoform-of-the-human-ifnss-receptor-isol-as-a-potential-therapeutic-molecule-for-multiple-sclerosis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ibima.eu\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/Human-IFNs-receptor-iSOL.png\",\"datePublished\":\"2024-07-17T11:42:23+00:00\",\"dateModified\":\"2024-07-17T11:42:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/recombinant-soluble-isoform-of-the-human-ifnss-receptor-isol-as-a-potential-therapeutic-molecule-for-multiple-sclerosis\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/recombinant-soluble-isoform-of-the-human-ifnss-receptor-isol-as-a-potential-therapeutic-molecule-for-multiple-sclerosis\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/recombinant-soluble-isoform-of-the-human-ifnss-receptor-isol-as-a-potential-therapeutic-molecule-for-multiple-sclerosis\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ibima.eu\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/Human-IFNs-receptor-iSOL.png\",\"contentUrl\":\"https:\\\/\\\/ibima.eu\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/Human-IFNs-receptor-iSOL.png\",\"width\":600,\"height\":200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/recombinant-soluble-isoform-of-the-human-ifnss-receptor-isol-as-a-potential-therapeutic-molecule-for-multiple-sclerosis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RECOMBINANT SOLUBLE ISOFORM OF THE HUMAN IFNSS RECEPTOR (ISOL) AS A POTENTIAL THERAPEUTIC MOLECULE FOR MULTIPLE SCLEROSIS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\",\"name\":\"Ibima\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibima.eu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\",\"name\":\"prodriguez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"caption\":\"prodriguez\"},\"sameAs\":[\"https:\\\/\\\/ibima.eu\"],\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/author\\\/prodriguez\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"RECOMBINANT SOLUBLE ISOFORM OF THE HUMAN IFNSS RECEPTOR (ISOL) AS A POTENTIAL THERAPEUTIC MOLECULE FOR MULTIPLE SCLEROSIS - Ibima","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibima.eu\/es\/recombinant-soluble-isoform-of-the-human-ifnss-receptor-isol-as-a-potential-therapeutic-molecule-for-multiple-sclerosis\/","og_locale":"es_ES","og_type":"article","og_title":"RECOMBINANT SOLUBLE ISOFORM OF THE HUMAN IFNSS RECEPTOR (ISOL) AS A POTENTIAL THERAPEUTIC MOLECULE FOR MULTIPLE SCLEROSIS - Ibima","og_description":"Financed by: European Commission Programme: INEXT- INFRASTRUCTURE FOR NMR, EM AND X-RAYS FOR TRANSLATIONAL RESEARCH 2018 Grant Agreement ID:\u00a0CE-INFRA-INEXT-2018-01\u00a0 \u00a0 Contact:\u00a0Laricchia-Robbio, Leopoldo Implementation Centre:\u00a0Hospital\u00a0Regional Universitario de M\u00e1laga Research group of IBIMA involved:\u00a0Neuroimmunology and Neuroinflammation  ","og_url":"https:\/\/ibima.eu\/es\/recombinant-soluble-isoform-of-the-human-ifnss-receptor-isol-as-a-potential-therapeutic-molecule-for-multiple-sclerosis\/","og_site_name":"Ibima","article_published_time":"2024-07-17T11:42:23+00:00","article_modified_time":"2024-07-17T11:42:26+00:00","og_image":[{"width":600,"height":200,"url":"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/07\/Human-IFNs-receptor-iSOL.png","type":"image\/png"}],"author":"prodriguez","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"prodriguez","Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ibima.eu\/recombinant-soluble-isoform-of-the-human-ifnss-receptor-isol-as-a-potential-therapeutic-molecule-for-multiple-sclerosis\/#article","isPartOf":{"@id":"https:\/\/ibima.eu\/recombinant-soluble-isoform-of-the-human-ifnss-receptor-isol-as-a-potential-therapeutic-molecule-for-multiple-sclerosis\/"},"author":{"name":"prodriguez","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"headline":"RECOMBINANT SOLUBLE ISOFORM OF THE HUMAN IFNSS RECEPTOR (ISOL) AS A POTENTIAL THERAPEUTIC MOLECULE FOR MULTIPLE SCLEROSIS","datePublished":"2024-07-17T11:42:23+00:00","dateModified":"2024-07-17T11:42:26+00:00","mainEntityOfPage":{"@id":"https:\/\/ibima.eu\/recombinant-soluble-isoform-of-the-human-ifnss-receptor-isol-as-a-potential-therapeutic-molecule-for-multiple-sclerosis\/"},"wordCount":268,"commentCount":0,"image":{"@id":"https:\/\/ibima.eu\/recombinant-soluble-isoform-of-the-human-ifnss-receptor-isol-as-a-potential-therapeutic-molecule-for-multiple-sclerosis\/#primaryimage"},"thumbnailUrl":"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/07\/Human-IFNs-receptor-iSOL.png","articleSection":["Proyectos de Investigaci\u00f3n"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ibima.eu\/recombinant-soluble-isoform-of-the-human-ifnss-receptor-isol-as-a-potential-therapeutic-molecule-for-multiple-sclerosis\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ibima.eu\/recombinant-soluble-isoform-of-the-human-ifnss-receptor-isol-as-a-potential-therapeutic-molecule-for-multiple-sclerosis\/","url":"https:\/\/ibima.eu\/recombinant-soluble-isoform-of-the-human-ifnss-receptor-isol-as-a-potential-therapeutic-molecule-for-multiple-sclerosis\/","name":"RECOMBINANT SOLUBLE ISOFORM OF THE HUMAN IFNSS RECEPTOR (ISOL) AS A POTENTIAL THERAPEUTIC MOLECULE FOR MULTIPLE SCLEROSIS - Ibima","isPartOf":{"@id":"https:\/\/ibima.eu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ibima.eu\/recombinant-soluble-isoform-of-the-human-ifnss-receptor-isol-as-a-potential-therapeutic-molecule-for-multiple-sclerosis\/#primaryimage"},"image":{"@id":"https:\/\/ibima.eu\/recombinant-soluble-isoform-of-the-human-ifnss-receptor-isol-as-a-potential-therapeutic-molecule-for-multiple-sclerosis\/#primaryimage"},"thumbnailUrl":"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/07\/Human-IFNs-receptor-iSOL.png","datePublished":"2024-07-17T11:42:23+00:00","dateModified":"2024-07-17T11:42:26+00:00","author":{"@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"breadcrumb":{"@id":"https:\/\/ibima.eu\/recombinant-soluble-isoform-of-the-human-ifnss-receptor-isol-as-a-potential-therapeutic-molecule-for-multiple-sclerosis\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibima.eu\/recombinant-soluble-isoform-of-the-human-ifnss-receptor-isol-as-a-potential-therapeutic-molecule-for-multiple-sclerosis\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ibima.eu\/recombinant-soluble-isoform-of-the-human-ifnss-receptor-isol-as-a-potential-therapeutic-molecule-for-multiple-sclerosis\/#primaryimage","url":"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/07\/Human-IFNs-receptor-iSOL.png","contentUrl":"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/07\/Human-IFNs-receptor-iSOL.png","width":600,"height":200},{"@type":"BreadcrumbList","@id":"https:\/\/ibima.eu\/recombinant-soluble-isoform-of-the-human-ifnss-receptor-isol-as-a-potential-therapeutic-molecule-for-multiple-sclerosis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ibima.eu\/es\/"},{"@type":"ListItem","position":2,"name":"RECOMBINANT SOLUBLE ISOFORM OF THE HUMAN IFNSS RECEPTOR (ISOL) AS A POTENTIAL THERAPEUTIC MOLECULE FOR MULTIPLE SCLEROSIS"}]},{"@type":"WebSite","@id":"https:\/\/ibima.eu\/es\/#website","url":"https:\/\/ibima.eu\/es\/","name":"Ibima","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibima.eu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635","name":"prodriguez","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","caption":"prodriguez"},"sameAs":["https:\/\/ibima.eu"],"url":"https:\/\/ibima.eu\/es\/author\/prodriguez\/"}]}},"_links":{"self":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts\/39550","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/comments?post=39550"}],"version-history":[{"count":4,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts\/39550\/revisions"}],"predecessor-version":[{"id":43721,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts\/39550\/revisions\/43721"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/media\/39552"}],"wp:attachment":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/media?parent=39550"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/categories?post=39550"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/tags?post=39550"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}